Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2021-06-02
- Target Recruit Count
- 120
- Registration Number
- NCT04760431
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Peking University International Hospital, Beijing, Beijing, China
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-06-04
- Target Recruit Count
- 60
- Registration Number
- NCT04717531
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2020-12-24
- Target Recruit Count
- 80
- Registration Number
- NCT04683445
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 130
- Registration Number
- NCT04680442
- Locations
- 🇧🇷
Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda, São Paulo, Brazil
🇧🇷Irmandade Da Santa Casa De Misericórdia De Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 517
- Registration Number
- NCT04629846
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
🇨🇳Tianjin Medical University Cancer Institution & Hospital, Tianjin, Tianjin, China
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-05-03
- Target Recruit Count
- 39
- Registration Number
- NCT04588545
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Northwestern University, Evanston, Illinois, United States
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
CRAFT: the NCT-PMO-1602 Phase II Trial
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- German Cancer Research Center
- Target Recruit Count
- 175
- Registration Number
- NCT04551521
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany
🇩🇪Universitätsklinikum Freiburg, Freiburg, Germany
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 245
- Registration Number
- NCT04538742
- Locations
- 🇬🇧
Research Site, Buckhurst Hill, United Kingdom
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT04514419
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.